# COG Phase III Wilms Tumor

## Protocol Title

**AREN0534 Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor**

<table>
<thead>
<tr>
<th>COG</th>
<th>Principal Investigator</th>
<th>Study Coordinator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children’s Oncology Group</td>
<td>Joel Kaplan, DO, MPH</td>
<td>Wendy Bissette, RN, BS</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:joel.kaplan@carolinashealthcare.org">joel.kaplan@carolinashealthcare.org</a></td>
<td></td>
</tr>
</tbody>
</table>

## Status

Active

## Key Inclusion Criteria*

- Patients must be previously enrolled on AREN03B2
- Patients must be < 30 years old at the time of initial diagnosis
- The patient must have one of the following conditions to be eligible for AREN0534:
  - Synchronous or metachronous bilateral Wilms tumors; or
  - Unilateral Wilms tumor and aniridia, Beckwith-Wiedemann Syndrome, idiopathic hemihypertrophy, Simpson-Golabi-Behmel-Syndrome, Denys-Drash Syndrome or other associated genitourinary anomalies; or
  - Multicentric Wilms tumor or unilateral WT with contralateral nephrogenic rest(s) in a child under one year of age; or
  - Diffuse hyperplastic perilobar nephroblastomatosis; or
  - Wilms tumor arising in a solitary kidney.
- Adequate liver and cardiac function

## Key Exclusion Criteria*

- Patients must not have received systemic chemotherapy or radiation therapy prior to treatment on this study
- Pregnant or breastfeeding females

## Therapies

### Chemotherapy

- Vincristine
- Dactinomycin
- Doxorubicin
- Cyclophosphamide
- Etoposide
- Mesna
- Carboplatin

### Radiation

### Surgery

### Referrals

*Please contact for referrals and/or study information:*

**Wendy Bissette, RN**

Ph 704-355-9081

wendy.bissette@carolinashealthcare.org

* Additional criteria apply. 

rev. 02/11